Case Report: A case of rapamycin-eluting stent for the treatment of refractory stenosis of arteriovenous fistula stenosis

作者全名："Xiong, Yu; Tu, Bo; Zhang, Minglu; Chen, Bo; Lai, Qiquan; Chen, Jing; Chen, Ling; Wan, Ziming"

作者地址："[Xiong, Yu; Lai, Qiquan; Chen, Ling; Wan, Ziming] Chongqing Med Univ, Affiliated Hosp 1, Dept Nephrol, Chongqing, Peoples R China; [Tu, Bo; Chen, Bo] Chongqing Med Univ, Affiliated Hosp 1, Dept Ultrasonog, Chongqing, Peoples R China; [Zhang, Minglu] 941 Hosp PLA Joint Logist Support Force, Dept Ultrasonog, Xining, Peoples R China; [Chen, Jing] Southwest Hosp Jiangbei Area, 958 Hosp Chinese Peoples Liberat Army, Dept Nephrol, Chongqing, Peoples R China"

通信作者："Wan, ZM (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Nephrol, Chongqing, Peoples R China."

来源：FRONTIERS IN CARDIOVASCULAR MEDICINE

ESI学科分类：　

WOS号：WOS:001308778600001

JCR分区：Q2

影响因子：3.6

年份：2024

卷号：11

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：arteriovenous fistula; refractory stenosis; rapamycin-eluting stent; percutaneous transluminal angioplasty; end-stage renal disease

摘要："For patients with repeated stenosis of autologous arteriovenous fistula, percutaneous transluminal angioplasty (PTA) or bare metal stent placement had limited efficacy. Rapamycin was reported to inhibit neointimal hyperplasia and keep blood vessels patent. In this study, we reported a case with refractory stenosis, i.e., a short duration of patency maintenance after each repeated PTA, which was treated with a rapamycin-eluting stent (RES). The RES extended the patency duration from 4 to 5 months on average to 14 months. The stent was used to maintain dialysis for over 30 months. RES may be an effective way to treat refractory stenosis and salvage limited vascular resources."

基金机构：Appropriate Technology Promotion Project of Chongqing Health Commission

基金资助正文：No Statement Available